Skip to main content
Premium Trial:

Request an Annual Quote

David Altshuler

David Altshuler is leaving the Broad Institute of Harvard University and the Massachusetts Institute of Technology to join Vertex Pharmaceuticals as executive VP, global research and chief scientific officer. Altshuler was one of the four founding members of the Broad and has served as deputy director and chief academic officer since 2009. He also is currently a professor of genetics and medicine at Harvard Medical School and an adjunct professor of biology at MIT.

Altshuler has resigned from his position as a Vertex director and will begin his new role at the firm in early 2015.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.